













- Aspembitova AT. Indicators of hormonal levels in eating disorders in patients with metabolic syndrome. (Published in Russian). *Lechaschiy vrach*. 2017; 10:92-95
12. Cipolla-Neto GG, Amaral FG, Afeche SC, Tan DX, Reiter RG. Melatonin, energy metabolism and obesity: a review. *G. Pineal. Res*, 2014; 56 (4):371-81.
13. Szewczyk-Golec K, Rajewski P, Gackowski M et al. Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie – Restricted Diet. *Oxid Med. Cell Longev*. 2017; 2017:8494107
14. Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct antihypertensive agent. *Clinical and Experimental Pharmacology and Physiology*. 2018; 45(8)
15. Grigore C, Stoian J, Grigore O, Brucknem JV Melatonin Level Modification after Ramipril Treatment for Hypertension. *Conference At Prague Czech Republic*, January 2011 ISBN: 978-1-61804-036-7
16. Mazdzan M, Chalubinski M, Wojdan K, and Broncel M. The effect of melatonin on circadian blood pressure in patients with tipe 2 diabetes and essential hypertension. *Arch. Med Sei*. 2014; 10(4):669-675.
17. Brinn NR, Candhi MA. A Review of the Role of Melatonin in Irritable Bowel Syndrome. *American Journal of Pharmacy and Health Research* 2014; 2(12):1-16.
18. Levin YAI, Kovrov GV, Poluektov MG et al. Insomnia: modern diagnostic and therapeutic approaches. *E'jdos Media. Protocol for patients with sleep disorders*. <http://sleepmed.ru> (Published in Russian). 2005.116
19. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. *Vascular Health and Risk Management*. 2011; 9:7577-584
20. Mazur M, Furgala A, Jablonski K, Mach T, Thor P. Autonomic nervous system activity in conspiracy-predominant irritable bowel syndrome patients. *Med. Sci Monit*. 2012; 18(8):493-499
21. Dragoi CM, Nicolae AG, Popa DE, Dumitrescu JB, Arsene AU, DrigoreC, Dinu-Pirvu C. Oxidative Stress and metabolic profiles assessment after melatonin and irbesafran co-administration in a novel pharmaceutical formulation. *Endocrine Abstracts*. 2017; 49 EP376]
22. Pechanova O, Ludovit P, Simko F. Peripheral and Central Effects of Melatonin on Blood Pressure Regulation. *Int. J. Mol. Sci* 2014; 15(10):17920-17937.
23. Vizir VA, Sodomov AS, Demidenko OV Duration of sleep as a risk factor for cardiovascular disease. (Published in Ukrainian). *Arterialna hipertenzia*. 2013; 1(27).
24. Ben Wang, Rugiao Duan, Liping Duan. Prevalence of sleep disorder in irritable bowel syndrome: Asystematic review with meta-analysis. *Saudi J. Gastroenterol*. 2018; 24(3):141-150
25. Patel Ami, Hasak S, Casseli B, Corba MS, Vivio EE, Kumar M, Gawali C, Sayuk GS. Effects of Disturbed Sleep on Gastrointestinal and Somatic Pain Symptoms in JBS. *Aliment. Pharmacol. Ther*. 2016; 44(3):246-258
26. Sun-Woo Jun-Sang, Hwangbo Young, Kim Won-Joo, Chu Min Kyung, Yun Chang-Ho, Yang Kwang JK. Prevalence, Sleep Characteristics and comorbidities in a population at high risk for obstructive sleep apnea: A nationwide questionnaire study in South Korea. *Plos One*. 2018; 13(2):1/14-14/14.
27. Tilea J, Petra D, Ardeleanu E, Hutanu A, Varga A. Clinical Conditions and Predictive Markers of Non-Dipper Profile in Hypertension. *Acta Medica Marisiensis*. 2018; 64(1):10-16.
28. Mao Y, Liz Chen K, Yu H Zhangs S.,Jiang M, Ma Y, Liang C et al. Antinoceptive Effect of Ghrelin in a Rat Model of Irritable bowel Syndrome Involves TRPV1 Opioid Systems. *Cell Physical Biochem*. 2017; 43:518-530.
29. Tesaro M, Schinzari E, Caramanti M, Lauro R, Cardilo C. Cardiovascular and metabolic effects of ghrelin. *Curr. Diabets. Rew*. 2010; 6(4):228-235.